THE 60-SECOND GUIDE
Bremelanotide (PT-141)
Approved human use · product-specific labels.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Its approved product, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Desire-related distress is the clinical target, rather than a universal increase in sexual performance. [1]
Potential benefits
FDA-approved for certain premenopausal women with acquired, generalized HSDD causing marked distress or interpersonal difficulty. Acts through melanocortin receptors rather than the vascular mechanism used by erectile-dysfunction medicines. It is not approved to enhance sexual performance. [1]
Evidence & its limits
Vyleesi is not indicated for men, postmenopausal women, or sexual-performance enhancement. It transiently raises blood pressure and is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea and potentially persistent focal pigmentation are important trade-offs. [1]
Risks & unknowns
Common reactions include nausea, flushing, headache, vomiting, and injection-site reactions. Temporarily increases blood pressure and reduces heart rate; contraindicated with uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation may occur and may not resolve. [1]
Status & scope
Its approved product, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA approval letter
- FDA VYLEESI label
- VYLEESI prescribing information
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.